Michael Keyoung
Location: New York
Member Since: 2014
Dr. Keyoung is Managing Director and Head of North America for CBC Group, formerly known as C-Bridge Capital, a leading healthcare Private Equity firm. Dr. Keyoung is also Founding Managing Partner of Portola Capital Partners, a US healthcare-focused investment firm that invests and advises healthcare companies.
Previously, Dr. Keyoung served as President and CEO of Genexine Inc, a KOSDAQ-listed biotech company with a Billion plus market cap focused on developing innovative biologic drugs for cancer and rare diseases. He successfully helped lead clinical development in Europe and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe Pharma during his tenure including the creation of I-MAB, an innovative biotech listed in NASDAQ (IMAB).
Dr. Keyoung was President of Catalyst Biosciences (NASDAQ:CBIO), a research and clinical development biopharma company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Throughout his career, he has invested in biotech and medtech companies in the US, Europe, and Asia as an institutional investor and advised leading healthcare companies such as Eli Lilly, Bausch & Lomb, and Samsung Electronics/Samsung Biologics in their regional expansion to Asia or global drug development, commercial strategies and partnerships.
Dr. Keyoung currently serves as a Board member of Hugel Inc (KOSDAQ: A145020), Hugel America, AffaMed Therapeutics, InxMed and has served as Founding Board members of Everest Medicines (1952.HK) and I-Mab Biopharma (NASDAQ:IMAB).
Dr. Keyoung received his Medical Doctorate and Ph.D. in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center as NIH’s MSTP and Tri-Institutional MD-PhD program graduate. Dr. Keyoung trained as a surgeon at the Univ. of California San Francisco Medical Center and was a biomedical fellow at Rockefeller University and Memorial Sloan-Kettering Cancer Center.